Kronos Bio, Inc.
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6
Ending by 2030
Dec 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 1, 2027The maintenance fee for 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma (US 9,120,811) comes due Mar 1, 2027. Unpaid by Sep 1, 2027, it lapses early.
- 2 fees due Jun 15 to 19, 2027 · next Jun 15
Recent changes
- 3 terms have ended since Aug 23, 2026
- Oct 9 US 10,093,684 SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS SYK INHIBITORS · lapsed on the fee record
- Oct 9 US 10,092,583 Imidazopyridines Syk Inhibitors · lapsed on the fee record
- Sep 25 US 10,080,756 Combination Methods for Treating Cancers · lapsed on the fee record
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,450,321 | 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor In force · USPTO record | In force | USPTO record | |
| US 8,455,493 | Imidazopyrazine Syk Inhibitors In force · High confidence | In force | High confidence | |
| US 8,962,835 | Imidazopyrazine Syk Inhibitors In force · High confidence | In force | High confidence | |
| US 9,120,811 | 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)imidazo[1,4-A]pyrazin-8-amine for treating leukemia or lymphoma In force · USPTO record | In force | USPTO record | |
| US 9,212,191 | 6-(2,3-Dihydro-1H-PYRIDO-[2,3-b][1,4]OXAZIN-7-YL)-N-(4-Morpholinophenyl)IMIDAZO[1,2-a]PYRAZIN-8-Amine AS A SPLEEN TYROSINE KINASE INHIBITOR In force · High confidence | In force | High confidence | |
| US 9,796,718 | 6-(BENZO[d]THIAZOL-5-YL)-N-(3,4-Dimethoxyphenyl)IMIDAZO[1,2-a]PYRAZIN-8-Amine In force · High confidence | In force | High confidence | |
| US 9,382,256 | Formulation of Syk inhibitors In force · USPTO record | In force | USPTO record | |
| US 9,657,023 | Polymorph of Syk inhibitors In force · USPTO record | In force | USPTO record | |
| US 9,918,939 | Formulation of Syk inhibitors In force · USPTO record | In force | USPTO record | |
| US 10,266,539 | Polymorph of Syk inhibitors In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 12: 11 patents in force now held by others · 19 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 2 no status recorded
Showing 1 to 4 of 4, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/957,450 | CRYSTALLINE FORMS OF 6-(6-AMINOPYRAZIN-2-YL)-N-(4-(4-(OXETAN-3-YL)PIPERAZIN-1-YL)PHENYL)IMIDAZO[l,2-a]PYRAZIN-8-AMINE AS SYK INHIBITORS | Nov 22, 2024 | Pending |
| 18/386,964 | Nov 3, 2023 | No status recorded | |
| 18/712,666 | Polymorphic and Salt Forms of (1S,3S)-N1-(5-(pentan-3-yl)pyrazolo[1,5-a]pyrimidin-7-yl) CYCLOPENTANE-1,3-Diamine | Nov 22, 2022 | Abandoned |
| 18/034,634 | Nov 4, 2021 | No status recorded |